Weitere Suchergebnisse zu "AstraZeneca":
 Aktien      Zertifikate      OS    


AstraZeneca: Lynparza Shows Improved Progression-free Survival Vs Chemotherapy




17.02.17 08:30
dpa-AFX


LONDON (dpa-AFX) - AstraZeneca (AZN.L) said, in the treatment of patients with HER2-negative metastatic breast cancer harbouring germline BRCA1 or BRCA2 mutations, Lynparza showed a statistically-significant and clinically-meaningful improvement in progression-free survival compared with those who received chemotherapy (capecitabine, vinorelbine or eribulin).

Initial findings from this Phase III OLYMPIAD study indicate that the safety profile of Lynparza was consistent with previous studies.


OLYMPIAD is a randomised, multi-center Phase III trial assessing the efficacy and safety of Lynparza (300 mg twice daily) to 'physician's choice' chemotherapy in 302 patients with HER2-negative metastatic breast cancer with germline BRCA1 or BRCA2 mutations, which are predicted or suspected to be deleterious. The international study was conducted in 19 countries.


AstraZeneca said its Phase III OLYMPIAD trial was the first positive randomised trial to evaluate the efficacy and safety of a PARP inhibitor beyond ovarian cancer. A full evaluation of the OLYMPIAD data is ongoing and the results will be submitted for presentation at a forthcoming medical meeting.


Copyright RTT News/dpa-AFX



MMMM





 
 
hier klicken zur Chartansicht

Aktuelle Kursinformationen mehr >
Kurs Vortag Veränderung Datum/Zeit
57,939 € 57,681 € 0,258 € +0,45% 27.03./20:19
 
ISIN WKN Jahreshoch Jahrestief
GB0009895292 886455 64,95 € 46,00 €
Handelsplatz Letzter Veränderung  Zeit
 
Tradegate (RT)
57,939 € +0,45%  19:21
Nasdaq OTC Other 61,89 $ +3,34%  19:13
Xetra 58,26 € +1,11%  17:28
Frankfurt 57,979 € +0,88%  17:47
Düsseldorf 57,60 € -0,35%  08:35
Stuttgart 57,61 € -0,35%  08:36
Berlin 57,60 € -0,35%  08:08
Hamburg 57,46 € -0,86%  08:09
Hannover 57,46 € -0,86%  08:09
München 57,45 € -0,91%  08:09
  = Realtime
Aktien des Tages
  


Mit der Anmeldung für den Newsletter "Aktien des Tages" stimme ich dem gleichzeitigen Erhalt des "GeVestor täglich" unseres Partners GeVestor zu.


Mit der Anmeldung für den Newsletter "Aktien des Tages" stimme ich dem gleichzeitigen Erhalt des "Investors Daily" unseres Partners FID Verlag zu.

Meistgelesene Artikel
Aktuelle Diskussionen
RSS Feeds




Bitte warten...